Generated by AI
OmniAb, Inc. is a biotechnology company that licenses discovery research technology to pharmaceutical and biotech companies and academic institutions. OmniAb’s platform is designed to support the discovery of next-generation therapeutics by creating and screening diverse antibody repertoires, helping partners identify optimal antibodies and other target-binding proteins for drug development. Its current offerings center on proprietary transgenic animal systems and related discovery tools that enable the generation of fully human antibodies and other therapeutic candidates. The company also provides integrated and customizable solutions that combine biological and computational methods, including antigen design, immunization, high-throughput screening, and data analysis. OmniAb serves a broad range of partners across the life sciences industry, positioning itself as a technology provider in the antibody discovery and biologics research market. Headquartered in Emeryville, California, OmniAb focuses on enabling research programs rather than developing and commercializing its own drugs.
Website5980 Horton Street
EmeryVille, CA, 94608
United States
The latest articles about OABI.
OmniAb reaches self-sustaining cash flow as its royalty platform gains traction.
Summary of Oct 30's posts. Generated by AI.
No summary yet.
No summary yet.
No summary yet.
Summary of Aug 17's posts. Generated by AI.
Investors talking about OABI also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.